Summary
Introduction
Ischaemic heart disease (IHD) is apparently uncommon among populations who eat large amounts of fatty fish and marine mammals. Protracted template bleeding times and lower levels of plasma triglycerides and higher concentrations of high-density-lipoprotein cholesterol (HDL cholesterol) have been reported in Greenland Eskimos compared with populations who eat small amounts of fish [ll. The plasma and platelet lipids of the Eskimos were unusual because they contained high proportions of eicosapentaenoic -acid (20 : 5 w3; EPA), an
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essential fatty acid that is normally found in trace amounts in the blood lipids of populations where IHD is prevalent. This must originate from diet, because it cannot be synthesized de novo. EPA, in common with arachidonic acid (20:4 w6; AA), can be converted into a series of prostaglandins and may influence haemostasis. However, unlike AA, EPA actually inhibits platelet aggregation both in vitro 12, 3, 41 and in vivo [51. It has been suggested, therefore, that dietary EPA may prevent IHD [61 by reducing thrombotic tendency and atherosclerosis.
Fish oils contain very substantial amounts of C20-22 w3 polyunsaturated fatty acids 171, notably EPA and docosahexaenoic acid (22 : 6 03; DHA), which are ultimately derived from linolenic acid (18:3 w3). Vegetable oils, which are usually rich in linoleic acid (1 8 : 2 w6), are devoid of EPA and DHA and fats from land animals only contain trace amounts. A daily supplement of 20 ml of cod liver oil taken for 6 weeks by healthy male volunteers prolonged template bleeding time and led to a marked fall in plasma triglyceride concentrations and to a slight increase in HDL cholesterol concentrations [81. Moreover, EPA and DHA displaced AA and docosatetraenoic acid (22:4 w6), which are derived from linoleic acid (18:2 w6), form erythrocyte and platelet lipids. This paper concerns a different fish oil supplement called MaxEPA. This oil contains about twice as much EPA and DHA as cod liver oil and only small amounts of C20-22 monoenes and negligible amounts of vitamin D. The influence of MaxEPA was also compared with one of linseed oil, which is rich in linolenic acid (18:3 w3).
Subjects, materials and methods
The subjects of the study were staff and students of Queen Elizabeth College. Consent was obtained from the College Ethical Committee and from individuals. Subjects were free from any medication from at least 10 days before measurement of platelet function. All the subjects completed a 7 day weighed food intake record and nutrient intakes and fatty acid intakes were calculated by computer using food tables [9, 101.
In the first experiment five subjects (three males and two females aged between 23 and 30 years) took a 5 mi teaspoon of linseed oil four times daily with meals for 2 weeks. After a break of at least 6 weeks, the same subjects took a similar amount of MaxEPA (Seven Seas Health Com, Hull, U.K.) for 2 weeks. Measurements were made before and after each experimental period.
In the second experiment, five male subjects aged 18 to 3 1 years of age took 20, 10 and 5 g of MaxEPAIday in random order for 3 week periods. Each experimental period was separated by a break of at least 6 weeks. Measurements were made at the beginning and at the end of each experimental period and 6 weeks after the final experimental period so that a total of four control measurements were made on each subject. At the 20 g dose, the oil was administered in a previously calibrated spoon; at the 10 g and 5 g levels, the oil was administered in 20 minim soft gelatin capsules (each capsule containing 1 g of oil). The oils and capsules were supplied by British Cod-liver Oils Ltd (Hull, U.K.). The encapsulated MaxEPA was from the same batch as the liquid oil used. All the oils used contained additional vitamin E (1000 unitdkg), citric acid (100 mg/kg) and the anti-oxidant dodecyl gallate (200 mg/kg). The fatty acid composition of the oils was determined by g.1.c. after conversion of the fatty acids into methyl esters. The vitamin A content of the MaxEPA was measured by the
Subjects fasted overnight from 22.00 hours and venous blood samples (50 ml) were drawn with minimum venous occlusion between 09.00 and 11.00 hours the following morning. The heights and weights of the subjects were recorded without sboes and wearing minimum indoor clothing. Bleeding times were measured in the second experiment using the Simplate I1 device (General Diagnostics, Warner-Lambert Ltd, Eastleigh, Hants., U.K.) each time a blood sample was taken. Platelet phosphoglyceride fatty acids, plasma total cholesterol, triglycerides and HDL cholesterol were determined as previously described [81.
Platelet aggregation was studied in the second experiment by the method of Born [121 using a Payton dual-channel aggregometer (Payton Associates Ltd, Scarborough, Ontario, Canada) commencing 1 h after, and being completed within 2 h of, taking the blood sample. Plateletrich plasma (PRP) was obtained from blood collected into a solution of 3 1 -3 g of trisodium citrate/l of water (1 p a d 9 parts of blood) after centrifugation (120 g for 15 min) at room temperature within 1 h of collecting the blood.
Platelet-poor plasma (PPP) was prepared by centrifuging the remaining citrated blood at 1500 g for 15 min at room temperature. PRP was adjusted to 250 000 plateletslpl with autologous PPP; platelet counts were made on a Coulter ZBI counter (Coulter Instruments, Luton, Beds, U.K.) fitted with a 70 pl orifice tube. Portions (0.5 ml) of the adjusted PRP were stirred at 1000 rev./min at 37OC. Transmitted light was adjusted to 90% for PPP and to 10% for PRP. Collagen (HormeChemie, Munchen, West Germany) and a prostaglandin endoperoxide analogue U466 19 (a gift from Dr John Pike, Upjohn Chemical Company, Kalamazoo, MI, U.S.A.) were used to provoke aggregation. Compound U466 19 was dissolved in ethanol and stored at 4OC; dilutions of the solution were made freshly each day with iso-osmotic saline (8.9 g of NaCl/l of water). Collagen dilutions were similarly made up with saline each day. Aggregating agent (10 pl) was added to 0.5 ml of PRP to induce aggregation. In order to determine whether the aggregation was dependent upon prostaglandin production, adjusted PRP samples were preincubated for 2 min with 10 pl of a freshly made solution of indomethacin (1 mg/ml of 50 mM-Tris buffer, pH 7.5; the indomethacin was dissolved in a small amount 1 M-Tris buffer, pH 8.4, before dilution). The parameters used to quantify the platelet aggregation were the maximum rate of change in light transmittance (V,,,=), the change in light transmittance after 2 min (TmaX.) and the time elapsed between the addition of the reagent and a rise in light transmittance above the base-line (lag time).
A paired-sample t-test was used for the statistical analyses in the first experiment. Analysis of variance was used for comparison of the results in the second experiment using the techniques described by Campbell 131 for dose-response experiments.
Results
The fatty acid composition of the oils used is shown in Table 1 . The amounts of 0 3 fatty acids provided by the supplements are shown in Table   2 . The MaxEPA supplement contained small amounts only of C20-22 monoenes and vitamin A (57 pg/g), considerably less than cod liver oil. The usual diets of the.subjects provided 40 & 1.8% of the energy intake as fat, with a polyunsaturatedlsaturated fatty acid ratio of 0.3 ? 0.05. Linoleic acid( 18: 2 06). and linolenic acid (18:3 03) intakes were 10 ? 1.6 g/day and 1.3 f 0.11 glday respectively or, expressed as a proportion of the total energy intake, 4.0 & 0.51% and 0.57 f 0.08%. Intakes of EPA and DHA from the diet were not calculated as the food composition data for these fatty acids are unreliable. However, the diets of the subjects contained only small amounts of fish.
There was no evidence of any significant change in body weight with the supplements. In the first experiment, plasma lipid concentrations were not influenced by the linseed oil supplement. However, the MaxEPA supplement in the same subjects led to a significant fall in plasma triglyceride concentrations (P < 0.02); plasma HDL cholesterol concentrations also tended to be increased but this was not statistically significant (Table 3 ). In the second experiment, the concentrations of all the lipids appeared to be influenced by the MaxEPA supplement (Table 4) . HDL cholesterol tended to be increased and total cholesterol lowered at the 20 glday dose but not at lower doses (both P < 0.05). Plasma triglyceride concentrations were substantially lowered at both the 10 g and 20 glday dose (P < Despite the high intake of linolenic acid (1 8 : 3 0 3 ) by the subjects on the linseed oil supplement, the proportion of this fatty acid in the platelet lipids was small. However, the linseed oil supplement did lead to a slight increase in the proportion of EPA (20:5 0 3 ) in the platelet lipids with a slight decrease in that of docosateraenoic acid (22:4 w6) but that of DHA (22 : 6 w3) was unchanged (Table 5) ; the ratio of
0.01).
AA/EPA fell from 50 : 1 to 20 : 1. The MaxEPA supplement led to large increases in the proportion of EPA and DHA in the platelet phosphoglycerides with corresponding falls in the proportions of AA and docosatetraenoic acid (22 :4 06); the ratio of AA/EPA fell from 33 : 1 to 6 : 1. The proportion of docosapentaenoic acid (22:5 w3) was not estimated in the first experiment because of a g.1.c. artifact in some of the samples originating from the sodium methoxide reagent that had a retention time on the Silar 1OC column similar to that of methyl docosapentaenoate (22 : 5 w3). Svennerhqlm [ 141 reported a similar artifact when using this reagent for the transmethylation of brain phosphoglycerides. This problem was not encountered in the second experiment.
Striking increases in the proportions of EPA and DHA with corresponding decreases in AA and docosatetraenoic acid (22:4 016) were observed even at intakes as low as 5 glday of MaxEPA (Table 6 ). At the 10 glday and 20 glday doses, the fall in AA was substantial; a significant reduction in the proportion of 6 dihomolinolenic acid (20 : 3 w6) also occurred at these doses. The proportion of docosapentaenoic acid (22 : 5 w3) was also considerably increased by the supplement, even though the intake of this fatty acid was small. The ratio of AAIEPA fell from 32: 1 in the control periods to 11 : 1 at 5 g/day, 7 : 1 at 10 glday to 5 : 1 at 20 glday.
Platelet aggregation induced in vitro by collagen, but not by compound U46619, was inhibited by the addition of indomethacin: the percentage inhibition of V,,,,,. was 30 & 3.0 with 10 pg/ml, 71 f 5.0 with 2 pg/ml and 79 f 6.8 with 1 pg/ml. This implies the aggregation was mediated mainly by the prostaglandin pathway at 1 and 2 pg/ml of collagen. The extent to which aggregation induced by collagen was inhibited by indomethacin did not change between control and treatment periods. A large response to 1 pug of collagenlml was obtained for all the subjects in both control and experimental periods. No significant change in any of the parameters of platelet aggregation measured in vitro could be detected with the MaxEPA supplement ( Table 7) . Bleeding time, however, tended to be prolonged by the supplement (P < 0.02), but did not follow any clear dose-dependent trend.
Discussion
The linseed oil supplement had only a small influence on the fatty acid composition of the This would suggest that a portion of the dietary EPA is chain-elongated to 22:5 0 3 . The proportion of DHA was considerably increased by the MaxEPA supplement but not by the linseed oil. This is consistent with the notion that linolenic acid is not readily converted into DHA by man. The lower proportions of AA and 22 : 4 0 6 imply that their synthesis from linoleic acid (18 : 2 0 6 ) was decreased.
Despite these changes in fatty acid composition platelet aggregation induced by collagen and the prostaglandin analogue U46619 did not appear to be altered. Aggregation was studied using these agents because studies in vitro showed that platelet aggregation induced by them was strongly inhibited by the addition of the sodium and potassium salts of EPA [2, 31 or MaxEPA (T. A. B. Sanders 19 N. Bolster, unpublished work). Platelet aggregation is highly variable and is affected by many factors such as drugs, exercise, stress and salt intake. Platelet aggregation induced by low doses of collagen is readily inhibited by a wide variety of drugs, particularly non-steroidal anti-inflammatory drugs, which interfere with prostaglandin metabolism 1161. We took great care to exclude all medication. Our results show that platelet aggregation induced by both 2 pg and 1 pg of collagen/ml of PRP was mediated by prostaglandins because it was inhibited by the addition of indomethacin, which blocks the enzyme cyclo-oxygenase. Siess et al. 171 reported that platelet aggregation induced by 1 pg/ml of PRP was completely inhibited after 1 week in subjects who had consumed 500-800 g of mackerel daily; it was estimated that the daily amount of EPA provided by this diet was 7-11 g, an amount far greater than that provided by our supplement. However, the changes in platelet lipids reported by these workers were similar to those found in our subjects after consuming 20 g of MaxEPA daily for 3 weeks. Brox et al. [ 181 reported that platelet aggregation induced by 0.9 pg of collagen/ml of PRP was inhibited after 4 weeks in subjects who had taken 25 ml of cod liver oil daily, which according to the authors provided 1 ;4 g of EPA per day, for 4 weeks. The results of other studies using diets rich in EPA [8, 19, 201 , however, do not indicate any consistent change in platelet aggregation measured in vitro.
Several studies have shown that bleeding time is prolonged by a diet rich in fish oil [8, 19-211. In the present study there did seem to be a tendency for bleeding time to increase with the MaxEPA supplement. Bleeding time is thought to be controlled by prostaglandin metabolites of arachidonic acid with opposing effects: thromboxane A, produced in platelets causes vaso-constriction and aggregation; prostacyclin (prostaglandin IJ produced in the vessel wall antagonizes the effects of thromboxane A, 1221. Dyerberg el al. [61 originally postulated that the balance between thromboxane and prostacyclin would be altered if EPA were the major prostaglandin precursor instead of AA because thromboxane A, is only weakly active, whereas prostaglandin I, is strongly active [21. However, neither thromboxane A, nor prostaglandin I, are formed in large amounts in experimental animals fed diets rich in EPA [23, 241. Moreover, EPA is a poor substrate for fatty acid cyclo-oxygenase compared with AA 14, 25, 261 but is an effective competitive inhibitor in uitro [261. EPA, however, is a good substrate for platelet lipoxygenase [251. Several studies 117, 18, 211 have found that the production of thromboxane B,, the stable breakdown product of thromboxane A,, is lowered by diets rich in fish oil. Aspirin irreversibly blocks the cyclo-oxygenase enzyme and leads to a decrease in thromboxane synthesis and the total inhibition of platelet aggregation induced by 1 pg of collagenlml of PRP and prolongs bleeding time [271. Platelet aggregation induced by low doses of collagen is certainly not inhibited in subjects fed fish oil to the same extent as with low doses of aspirin. Therefore, other mechanisms besides impaired platelet aggregation are needed to explain the prolonged bleeding time caused by fish oil feeding. Thromboxane synthetase inhibitors, however, do not inhibit human platelet aggregation induced by low doses of collagen in uitro 128, 291, presumably because other prostaglandins produced by the platelets such as prostaglandin H, and prostaglandin E, are capable of causing aggregation. In experimental animals thromboxane synthetase inhibitors prolong bleeding time without inhibiting platelet aggregation induced by low doses of collagen [301. This has led to the view that the main role of thromboxane A, is to cause vasoconstriction. It is possible that EPA or some other component in fish oil leads to the production of a thromboxane synthetase inhibitor. A likely candidate would be a metabolite of the lipoxygenase pathway. In addition to its possible influence on prostaglandin metabolism, dietary EPA has been shown to lower whole-blood viscosity 1311. Perhaps the most convincing evidence for the influence of fish oils on platelet vessel wall interactions is their protective effect on experimental cerebral infarction in cats [321 and experimental myocardial infarction in dogs [33]. In both these studies infarct size was reduced and there was evidence of improved collateral circulation. In the latter study platelet fatty acids were modified considerably by the diet but platelet aggregation measured in uitro was not affected.
Many studies using fish oils or fatty fish have only considered the influence of EPA and not the other 0 3 fatty acids. DHA is usually a major component of fish oils and it is the major polyunsaturated fatty acid found in human brain and retina. DHA is thought to play an important role in retinal and brain function [341. Moreover, heart lipids also have a high affinity for DHA in experimental animals (351 (T. A. B. Sanders & F.
Roshanai, unpublished work). Recently it has
been shown that DHA can be converted into prostaglandin derivatives [361. We have found that the potassium salts of DHA added to PRP inhibited platelet aggregation induced by low doses of collagen and compound U46619 at similar concentrations to EPA (T. A. B. Sanders & N. Bolster, unpublished work). The role DHA may play in haemostasis and cardiac function deserves attention.
The ability of dietary 0 3 fatty acids to lower plasma total cholesterol concentration is well documented [71 and the potency increases with the degree of unsaturation. This is in accord with our observation that the linseed oil supplement, which provided 9.4 g of 18:3 0 3 , had no influence on plasma cholesterol concentrations, whereas the mean value was slightly lowered by 20 g of MaxEPA, which provided about 7 g of C20-22 0 3 fatty acids. Our findings show that plasma triglyceride concentrations may be decreased by as little as 10-g of MaxEPA per day, ' which provided about 3.5 g of C20-22 0 3 fatty acids. This is in agreement with our early study using 20 ml of cod-liver oil per day, which provided about 4 g of C20-22 0 3 fatty acids. The failure of the linseed oil supplement to influence plasma triglyceride concentrations implies that only C20-22 0 3 fatty acids and not linolenic acid (18:3 w3) show this hypotriglyceridaemic effect. Bronsgeest-Schoute et al.
[37] found about 7 g of C20-22 w3 fatty acidslday but not lower doses decreased plasma triglycerides concentrations. However, these workers were using a cod liver oil concentrate. This concentrate was a mixture of non-esterified fatty acids and methyl esters and was prepared by removing the more saturated fatty acids as urea adducts. It has been known for some time [7,38, 391 that fatty acid esters of fish oils prepared in this way often yield different results from those expected. Firstly the absorption of the fatty acids may be poor compared with that of the triglyceride and secondly peroxidized fatty acids and their breakdown products such as aldehydes, hydroxy acids and ketones are concentrated in the non-urea adductable fraction [401.
Our The average intake of C20-22 0 3 fatty acids by Greenland Eskimos is about 14 g/day [l]; considerably more than the amounts used in our experiments. Our supplements were considerably greater than the 0.1 g/day provided by the average British diet 1501 but were comparable with the average intake of these fatty acids by the Japanese (511. In conclusion our results suggest that modest amounts of fish oil or correspondingly larger amounts of fatty fish may significantly influence blood lipids and haemostatic function.
